Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 24, 2015
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities.
Key Financial Metrics and Transaction Details
This filing reports a financing arrangement rather than standard periodic financial results (revenue, profit, or cash flow). Key transaction metrics include:
- Facility Size: Up to $10.0 million in common stock available for sale over a 36-month period.
- Initial Issuance: 250,000 shares of Common Stock issued immediately to Lincoln Park Capital Fund, LLC.
- Purchase Limits:
- Regular Purchases: Up to 100,000 shares (or 200,000 depending on price) per business day, capped at $500,000 per transaction.
- Beneficial Ownership Cap: Lincoln Park cannot acquire more than 9.99% of outstanding shares.
- Pricing: Based on prevailing market prices, subject to a floor price defined in the agreement.
- Use of Proceeds: General corporate purposes and working capital requirements.
Material Changes Versus Prior Period
The filing does not provide comparative financial data (e.g., revenue or earnings changes) as it is a current report regarding a specific corporate event. The material change is the establishment of a new equity financing facility with Lincoln Park Capital Fund, LLC, providing the Company with a mechanism to raise capital on an as-needed basis.
Guidance, Outlook, and Risks
Management Commentary: The Company retains sole discretion to direct purchases and may terminate the agreement at any time without cost or penalty. Actual sales depend on market conditions and the Company's funding determinations.
Risks and Contingencies:
- Dilution: Future sales of shares will result in dilution to existing shareholders.
- Market Conditions: Sales are contingent on the stock price not falling below a specific floor price.
- Uncertainty of Proceeds: The net proceeds are not guaranteed and depend on the frequency and price of future sales.
- Short Selling Restrictions: Lincoln Park has covenanted not to engage in short selling or hedging of Company shares.
Investor Verification Checklist
- Verify the specific "floor price" and "threshold price" defined in the attached Purchase Agreement (Exhibit 10.1) to understand pricing constraints.
- Confirm the current outstanding share count to assess the dilution impact of the 250,000 shares already issued and the potential $10.0 million facility.
- Review the Registration Rights Agreement (Exhibit 10.2) to understand the timeline for the registration statement effectiveness required to activate the facility.
- Monitor future 8-K filings for actual sales transactions and the aggregate amount raised under this agreement.